Francesco Grossi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1634903/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 2078-2092.	27.0	4,701
2	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2020, 38, 1505-1517.	1.6	710
3	First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet, The, 2021, 397, 375-386.	13.7	638
4	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncology, The, 2020, 21, 914-922.	10.7	503
5	Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 1835-1842.	1.6	421
6	Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma. Journal of Clinical Oncology, 2006, 24, 1443-1448.	1.6	276
7	Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. Journal of Cancer Research and Clinical Oncology, 2019, 145, 479-485.	2.5	253
8	Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers, 2020, 12, 546.	3.7	177
9	Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 713-721.	10.7	157
10	ILâ€8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. International Journal of Cancer, 2009, 125, 887-893.	5.1	151
11	Crizotinib in <i>MET</i> -Deregulated or <i>ROS1</i> -Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. Clinical Cancer Research, 2019, 25, 7312-7319.	7.0	139
12	Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1319-1327.	1.1	138
13	PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells. Frontiers in Immunology, 2019, 10, 1242.	4.8	130
14	Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. Journal of Clinical Oncology, 2017, 35, 1281-1287.	1.6	126
15	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of Oncology, 2016, 27, 417-423.	1.2	122
16	Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer, 2019, 129, 35-40.	2.0	122
17	Pleural and Peripheral Lung Lesions: Comparison of US- and CT-guided Biopsy. Radiology, 2013, 266, 930-935.	7.3	115
18	Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2012, 61, 1463-1472.	4.2	110

#	Article	IF	CITATIONS
19	Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. British Journal of Cancer, 2008, 99, 51-56.	6.4	107
20	The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. Journal of Translational Medicine, 2019, 17, 74.	4.4	103
21	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. , 2019, 7, 316.		102
22	Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer, 2006, 107, 2842-2849.	4.1	98
23	Exosomes: a new horizon in lung cancer. Drug Discovery Today, 2017, 22, 927-936.	6.4	90
24	Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. British Journal of Cancer, 2013, 109, 552-558.	6.4	89
25	Use of nivolumab in elderly patients with advanced squamous non–small-cell lung cancer: results from the Italian cohort of an expanded access programme. European Journal of Cancer, 2018, 100, 126-134.	2.8	83
26	Low-Dose Computed Tomography Screening for Lung Cancer and Pleural Mesothelioma in an Asbestos-Exposed Population: Baseline Results of a Prospective, Nonrandomized Feasibility Trial—An Alpe-Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002). Oncologist, 2007, 12, 1215-1224.	3.7	82
27	Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges. Cancers, 2020, 12, 17.	3.7	82
28	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. , 2021, 9, e002421.		80
29	Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey. European Journal of Cancer, 2020, 132, 17-23.	2.8	79
30	Italian Nivolumab Expanded Access Program inÂNonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. Journal of Thoracic Oncology, 2018, 13, 1146-1155.	1.1	77
31	Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. European Journal of Cancer, 2003, 39, 1242-1250.	2.8	76
32	Clinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer. Oncologist, 2008, 13, 14-20.	3.7	73
33	Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients. Oncologist, 2018, 23, 936-942.	3.7	69
34	ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. British Journal of Cancer, 2013, 108, 1695-1703.	6.4	67
35	Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non‧mall Cell Lung Cancer: A Review of the Literature. Oncologist, 2007, 12, 451-464.	3.7	65
36	Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach. Oncologist, 2009, 14, 497-510.	3.7	64

#	Article	IF	CITATIONS
37	Future Scenarios for the Treatment of Advanced Non-Small Cell Lung Cancer: Focus on Taxane-Containing Regimens. Oncologist, 2010, 15, 1102-1112.	3.7	64
38	Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System. Frontiers in Oncology, 2014, 4, 242.	2.8	63
39	The activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma. European Journal of Cancer, 2003, 39, 353-357.	2.8	62
40	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%. Cancer Immunology, Immunotherapy, 2020, 69, 2209-2221.	4.2	60
41	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. , 2020, 8, e001403.		57
42	NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncology, The, 2018, 19, 799-811.	10.7	56
43	Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. International Journal of Molecular Sciences, 2021, 22, 4774.	4.1	55
44	Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer. European Journal of Cancer, 2019, 123, 72-80.	2.8	54
45	The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer. Critical Reviews in Oncology/Hematology, 2001, 37, 61-67.	4.4	53
46	Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer. Frontiers in Immunology, 2020, 11, 125.	4.8	53
47	In Vitro Study of CI-994, a Histone Deacetylase Inhibitor, in Non-Small Cell Lung Cancer Cell Lines. Oncology Research, 2005, 15, 39-48.	1.5	52
48	Messinian Lago-Mare deposits near the Strait of Gibraltar (Malaga Basin, S Spain). Palaeogeography, Palaeoclimatology, Palaeoecology, 2010, 285, 264-276.	2.3	51
49	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 ExpressionÂ≥ 50% and Their Relationship With Clinical Outcomes. Clinical Lung Cancer, 2020, 21, 498-508.e2.	2.6	50
50	Introduction of the beta isozyme of protein kinase C accelerates induced differentiation of murine erythroleukemia cells Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 4417-4420.	7.1	49
51	Geography of clinical cancer research publications from 1995 to 1999. European Journal of Cancer, 2003, 39, 106-111.	2.8	49
52	A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). Annals of Oncology, 2013, 24, 2382-2389.	1.2	49
53	Paratethyan Ostracod immigrants in Italy during the Late Miocene. Geobios, 2007, 40, 325-337.	1.4	48
54	Understanding the checkpoint blockade in lung cancer immunotherapy. Drug Discovery Today, 2017, 22, 1266-1273.	6.4	48

#	Article	IF	CITATIONS
55	Gender-related difference in ST-elevation myocardial infarction treated with primary angioplasty: a single-centre 6-year registry. European Journal of Preventive Cardiology, 2012, 19, 233-240.	1.8	47
56	Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases. Journal of Thoracic Oncology, 2011, 6, 1260-1266.	1.1	46
57	Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). European Journal of Cancer, 2013, 49, 2815-2822.	2.8	45
58	Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab. Journal of Clinical Medicine, 2019, 8, 1011.	2.4	45
59	Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology, The, 2021, 22, 1438-1447.	10.7	45
60	Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non–Small Cell Lung Cancer: ¹⁸ F-FDG PET/CT Study. Journal of Nuclear Medicine, 2017, 58, 1764-1769.	5.0	44
61	Comparison Between ¹⁸ F-FDG PET–Based and CT-Based Criteria in Non–Small Cell Lung Cancer Patients Treated with Nivolumab. Journal of Nuclear Medicine, 2020, 61, 990-998.	5.0	44
62	IL-12 Can Target Human Lung Adenocarcinoma Cells and Normal Bronchial Epithelial Cells Surrounding Tumor Lesions. PLoS ONE, 2009, 4, e6119.	2.5	43
63	Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non–Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial. Clinical Lung Cancer. 2011. 12. 407-411.	2.6	43
64	Ramucirumab: preclinical research and clinical development. OncoTargets and Therapy, 2014, 7, 1997.	2.0	43
65	Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. International Journal of Molecular Sciences, 2017, 18, 1035.	4.1	39
66	Identification and Management of Immune Checkpoint Inhibitor–Related Myocarditis: Use Troponin Wisely. Journal of Clinical Oncology, 2019, 37, 2201-2205.	1.6	39
67	Next Generation Sequencing in Non-Small Cell Lung Cancer: New Avenues Toward the Personalized Medicine. Current Drug Targets, 2015, 16, 47-59.	2.1	38
68	Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review. Cancers, 2021, 13, 1794.	3.7	38
69	Outpatient Hysteroscopic Polypectomy in 237 Patients: Feasibility of a One-Stop "See-and-Treat― Procedure. Journal of Minimally Invasive Gynecology, 2004, 11, 500-504.	1.2	37
70	Arginase 2 is expressed by human lung cancer, but it neither induces immune suppression, nor affects disease progression. International Journal of Cancer, 2008, 123, 1108-1116.	5.1	37
71	Orbitally forced paleoenvironmental and paleoclimate changes in the late postevaporitic Messinian of the central Mediterranean Basin. Bulletin of the Geological Society of America, 2012, 124, 499-516.	3.3	35
72	Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGMâ,,¢ Platform. International Journal of Molecular Sciences, 2015, 16, 28765-28782.	4.1	35

#	Article	IF	CITATIONS
73	Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression. Clinical Lung Cancer, 2019, 20, 178-185.e2.	2.6	35
74	Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. Oncologist, 2019, 24, e1165-e1171.	3.7	35
75	The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer. ESMO Open, 2021, 6, 100078.	4.5	35
76	Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. World Journal of Gastroenterology, 2020, 26, 3542-3561.	3.3	35
77	Adjuvant chemotherapy for non-small cell lung cancer: Ready for clinical practice?. European Journal of Cancer, 2006, 42, 8-16.	2.8	34
78	Easternmost Mediterranean evidence of the Zanclean flooding event and subsequent surface uplift: Adana Basin, southern Turkey. Geological Society Special Publication, 2013, 372, 473-494.	1.3	34
79	Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. Targeted Oncology, 2015, 10, 393-404.	3.6	34
80	Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2008, 68, 183-196.	4.4	33
81	Late Messinian lago-mare ostracod palaeoecology: A correspondence analysis approach. Palaeogeography, Palaeoclimatology, Palaeoecology, 2008, 264, 288-295.	2.3	33
82	Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer. Drug Discovery Today, 2014, 19, 1671-1676.	6.4	33
83	Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases. Anticancer Research, 2019, 39, 4265-4271.	1.1	33
84	Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors. Pharmaceutics, 2021, 13, 653.	4.5	33
85	Management of Malignant Pleural Effusions. Drugs, 1998, 55, 47-58.	10.9	31
86	Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients. Molecular Cancer, 2013, 12, 97.	19.2	31
87	Role of microRNAs in malignant mesothelioma. Cellular and Molecular Life Sciences, 2014, 71, 2865-2878.	5.4	31
88	Smoking status during firstâ€line immunotherapy and chemotherapy in <scp>NSCLC</scp> patients: A case–control matched analysis from a large multicenter study. Thoracic Cancer, 2021, 12, 880-889.	1.9	30
89	Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain. Lung Cancer, 2011, 74, 529-534.	2.0	29
90	Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non–Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study. Journal of Thoracic Oncology, 2014, 9, 1704-1708.	1.1	29

#	Article	IF	CITATIONS
91	Coronavirus infection and immune system: An insight of COVID-19 in cancer patients. Critical Reviews in Oncology/Hematology, 2020, 153, 103059.	4.4	29
92	Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non–Small-Cell Lung Cancer in Elderly Patients. Journal of Thoracic Oncology, 2014, 9, 733-737.	1.1	28
93	Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 665-672.	1.1	28
94	Is Cyprideis agrigentina Decima a good paleosalinometer for the Messinian Salinity Crisis? Morphometrical and geochemical analyses from the Eraclea Minoa section (Sicily). Palaeogeography, Palaeoclimatology, Palaeoecology, 2015, 419, 75-89.	2.3	27
95	Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples. BMC Cancer, 2016, 16, 692.	2.6	27
96	Potential cardiac risk of immune heckpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects. Medicinal Research Reviews, 2018, 38, 1447-1468.	10.5	27
97	Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 2055-2062.	1.8	27
98	<p>Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options</p> . Cancer Management and Research, 2020, Volume 12, 675-686.	1.9	27
99	Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma. Oncotarget, 2017, 8, 68627-68640.	1.8	27
100	Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy. Lung Cancer, 2010, 69, S11-S17.	2.0	26
101	Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I–III Non-Small Cell Lung Cancer. Disease Markers, 2015, 2015, 1-18.	1.3	26
102	Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. Journal of Clinical Medicine, 2019, 8, 1566.	2.4	26
103	IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting. Cancers, 2020, 12, 3310.	3.7	25
104	PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 1461.	4.1	25
105	Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer. BMC Cancer, 2008, 8, 216.	2.6	24
106	Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data: An Alpe Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 014). Journal of Thoracic Oncology, 2010, 5, 1354-1360.	1.1	24
107	Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as α-mannosidase inhibitors and with antitumor activities against hematological and solid malignancies. Bioorganic and Medicinal Chemistry, 2010, 18, 3320-3334.	3.0	24
108	Pemetrexed for the treatment of non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2013, 14, 1545-1558.	1.8	24

#	Article	IF	CITATIONS
109	The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 1969-1976.	1.8	24
110	Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study. Cancer Immunology, Immunotherapy, 2019, 68, 1351-1358.	4.2	24
111	Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy. European Journal of Cancer, 2021, 150, 224-231.	2.8	24
112	Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer. British Journal of Cancer, 1999, 81, 310-315.	6.4	23
113	Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. Future Oncology, 2014, 10, 79-90.	2.4	23
114	DISRUPT: A randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane–platinum regimen as first-line therapy for metastatic non-small cell lung cancer. Lung Cancer, 2014, 85, 224-229.	2.0	23
115	Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non–Small Cell Lung Cancer. JAMA Oncology, 2018, 4, e183486.	7.1	23
116	Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis. Cancers, 2020, 12, 998.	3.7	23
117	Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines. Lung Cancer, 2001, 33, 27-39.	2.0	22
118	Informal Caregiving Burden in Advanced Non-small Cell Lung Cancer: The HABIT study. Journal of Thoracic Oncology, 2007, 2, 475-480.	1.1	22
119	Oral vinorelbine in the treatment of non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 1585-1599.	1.8	22
120	Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients. Molecular Medicine, 2019, 25, 15.	4.4	22
121	Novel treatment strategies for early-stage lung cancer: the oncologist's perspective. Journal of Thoracic Disease, 2020, 12, 3390-3398.	1.4	22
122	Buccal Mucosa Cells as In vivo Model to Evaluate Gefitinib Activity in Patients with Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 6518-6526.	7.0	21
123	Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer. ClinicoEconomics and Outcomes Research, 2012, 4, 31.	1.9	21
124	Afatinib for the treatment of advanced non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 889-903.	1.8	21
125	Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. Expert Opinion on Drug Safety, 2017, 16, 573-585.	2.4	21
126	Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds. Expert Opinion on Investigational Drugs, 2019, 28, 513-523.	4.1	21

#	Article	IF	CITATIONS
127	Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives. Expert Review of Respiratory Medicine, 2020, 14, 367-383.	2.5	21
128	Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review. International Journal of Molecular Sciences, 2021, 22, 2628.	4.1	21
129	Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatanib plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatanib—LUX-Lung 5 (LL5) Journal of Clinical Oncology. 2014. 32. 8019-8019.	1.6	21
130	Pretreatment and prospective assessment of endometrium in menopausal women taking tamoxifen for breast cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2007, 132, 101-106.	1.1	20
131	An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy. Lung Cancer, 2009, 64, 199-206.	2.0	20
132	Free drugs in clinical trials and their potential cost saving impact on the National Health Service: A retrospective cost analysis in Italy. Lung Cancer, 2013, 81, 236-240.	2.0	20
133	Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality?. Cancers, 2019, 11, 1095.	3.7	20
134	A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic. Cancers, 2020, 12, 2452.	3.7	20
135	"Earliest Zanclean age for the Colombacci and uppermost Di Tetto formations of the «Âlatest Messinian» northern Apennines: New palaeoenvironmental data from the Maccarone section (Marche) Tj ETQ	9q11140.78	343 14 rgBT /O
136	Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer. Expert Opinion on Biological Therapy, 2012, 12, 939-948.	3.1	19
137	A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer. Lung Cancer, 2012, 76, 465-471.	2.0	19
138	NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer. Oncologist, 2018, 23, 1133-e112.	3.7	19
139	Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentreÂreal-world study. European Journal of Cancer, 2021, 148, 24-35.	2.8	19
140	Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: A phase II trial from an Italian cooperative group. Acta Oncológica, 2006, 45, 168-174.	1.8	18
141	Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). British Journal of Cancer, 2012, 106, 658-665.	6.4	18
142	Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy. British Journal of Cancer, 2017, 116, 36-43.	6.4	18
143	Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer. Anticancer Research, 2008, 28, 507-13.	1.1	18
144	The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC). Annals of Oncology, 1999, 10, S13-S17.	1.2	17

#	Article	IF	CITATIONS
145	Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC). Critical Reviews in Oncology/Hematology, 2006, 58, 221-230.	4.4	17
146	Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2008, 67, 16-26.	4.4	17
147	CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine. Expert Opinion on Biological Therapy, 2018, 18, 829-835.	3.1	17
148	Developing a risk assessment score for patients with cancer during the coronavirus disease 2019 pandemic. European Journal of Cancer, 2020, 135, 47-50.	2.8	17
149	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2). , 2021, 9, e002619.		17
150	The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab. Cancers, 2021, 13, 3117.	3.7	17
151	Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?. World Journal of Radiology, 2017, 9, 27.	1.1	17
152	Maintenance chemotherapy in non-small cell lung cancer. Annals of Oncology, 2006, 17, ii67-ii70.	1.2	16
153	Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview. Future Oncology, 2014, 10, 2081-2096.	2.4	16
154	Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in Italy. Annals of Oncology, 2016, 27, vi425.	1.2	16
155	Impact of low-dose computed tomography screening on lung cancer mortality among asbestos-exposed workers. International Journal of Epidemiology, 2018, 47, 1981-1991.	1.9	16
156	Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A randomized study. Annals of Oncology, 2000, 11, 1413-1420.	1.2	15
157	CD133-Positive Cells from Non-Small Cell Lung Cancer Show Distinct Sensitivity to Cisplatin and Afatinib. Archivum Immunologiae Et Therapiae Experimentalis, 2015, 63, 207-214.	2.3	15
158	Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma. MicroRNA (Shariqah, United Arab Emirates), 2016, 5, 12-18.	1.2	15
159	Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer. Clinical and Experimental Metastasis, 2019, 36, 449-456.	3.3	15
160	Advances in treatment of mesothelioma. Expert Opinion on Pharmacotherapy, 2016, 17, 1197-1205.	1.8	14
161	Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. Cancers, 2020, 12, 2948.	3.7	14
162	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096846.	3.2	14

#	Article	IF	CITATIONS
163	Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non–small Cell Lung Cancer in the Italian National Health Service. Clinical Therapeutics, 2020, 42, 830-847.	2.5	14
164	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. Journal of Translational Medicine, 2021, 19, 270.	4.4	14
165	Tumor measurements on computed tomographic images of non–small cell lung cancer were similar among cancer professionals from different specialties. Journal of Clinical Epidemiology, 2004, 57, 804-808.	5.0	13
166	Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols. Bioorganic and Medicinal Chemistry, 2011, 19, 7720-7727.	3.0	13
167	Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy. Lung Cancer, 2018, 117, 64-69.	2.0	13
168	Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer. Expert Review of Respiratory Medicine, 2021, 15, 1427-1435.	2.5	13
169	Title is missing!. Annals of Oncology, 2000, 11, 101-110.	1.2	13
170	Abstract CT043: Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results from the KEYNOTE-189 study. Cancer Research, 2019, 79, CT043-CT043.	0.9	13
171	Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007). Lung Cancer, 2006, 52, 89-92.	2.0	12
172	Belagenpumatucel-L for the treatment of non-small cell lung cancer. Expert Opinion on Biological Therapy, 2015, 15, 1371-1379.	3.1	12
173	Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma. Medicine (United States), 2016, 95, e5447.	1.0	12
174	Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. Immunotherapy, 2019, 11, 873-879.	2.0	12
175	Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. Lung Cancer, 2019, 134, 210-217.	2.0	12
176	Metabolic Interplay between the Immune System and Melanoma Cells: Therapeutic Implications. Biomedicines, 2021, 9, 607.	3.2	12
177	5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. British Journal of Cancer, 2001, 84, 1023-1028.	6.4	11
178	Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001). Lung Cancer, 2004, 46, 99-106.	2.0	11
179	Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma. Journal of Thoracic Oncology, 2015, 10, e50-e52.	1.1	11
180	Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in <scp>NSCLC</scp> cell lines poorly responsive to reversible <scp>EGFR</scp> tyrosine kinase inhibitors. International Journal of Cancer, 2015, 137, 2947-2958.	5.1	11

#	Article	IF	CITATIONS
181	Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Cancers, 2019, 11, 125.	3.7	11
182	Facies analysis in the Second Cycle Messinian evaporites predating the early Pliocene reflooding: the Balza Soletta section (Corvillo Basin, central Sicily). Italian Journal of Geosciences, 2019, 138, 301-316.	0.8	11
183	Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial. ESMO Open, 2021, 6, 100051.	4.5	11
184	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. Cancer Immunology, Immunotherapy, 2022, 71, 865-874.	4.2	11
185	Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. Expert Opinion on Biological Therapy, 2014, 14, 1007-1017.	3.1	10
186	30 Immunotherapy in advanced NSCLC—from the â€~tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). ESMO Open, 2018, 3, e000298.	4.5	10
187	New insight into the Pleistocene deposits of Monte delle Piche, Rome, and remarks on the biochronology of Hippopotamus (Mammalia, Hippopotamidae) and Stephanorhinus etruscus (Mammalia, Rhinocerotidae) in Italy. Estudios Geologicos, 2015, 71, e026.	0.2	10
188	The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib. Cancer Chemotherapy and Pharmacology, 2012, 69, 1407-1412.	2.3	9
189	Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy. Current Clinical Pharmacology, 2018, 13, 76-84.	0.6	9
190	LBA1 First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743. Annals of Oncology, 2020, 31, S1441.	1.2	9
191	Triage process for the assessment of coronavirus disease 2019â€positive patients with cancer: The ONCOVID prospective study. Cancer, 2021, 127, 1091-1101.	4.1	9
192	First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Lung Cancer, 2022, 167, 8-16.	2.0	9
193	Information given to cancer patients on diagnosis, prognosis and treatment: the clinical oncologist's perspective. European Journal of Cancer, 2004, 40, 1850-1854.	2.8	8
194	Valutazione economica di erlotinib, docetaxel e pemetrexed nel trattamento di seconda linea del carcinoma polmonare non a piccole cellule. Pharmacoeconomics Italian Research Articles, 2007, 9, 113-124.	0.2	8
195	Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1783-1793.	2.5	8
196	P1.01-79 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-line (1L) Treatment of Advanced NSCLC. Journal of Thoracic Oncology, 2018, 13, S493.	1.1	8
197	The record of the Messinian salinity crisis in mobile belts: Insights from the Molise allochthonous units (southern Apennines, Italy). Palaeogeography, Palaeoclimatology, Palaeoecology, 2018, 503, 112-130.	2.3	8
198	PCSK9 is a promising prognostic marker in patients with advanced NSCLC. Cancer Immunology, Immunotherapy, 2020, 69, 491-492.	4.2	8

#	Article	IF	CITATIONS
199	Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study. Cancers, 2021, 13, 1324.	3.7	8
200	Severe hypocalcemia and life-threatening ventricular arrhytmias: case report and proposal of a diagnostic and therapeutic algorithm. Clinical Cases in Mineral and Bone Metabolism, 2015, 12, 265-8.	1.0	8
201	Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2016, 16, 1142-1154.	1.7	8
202	Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review. International Journal of Molecular Sciences, 2022, 23, 147.	4.1	8
203	Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients. Cytotechnology, 1996, 19, 215-219.	1.6	7
204	Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity International Journal of Oncology, 1999, 15, 787-92.	3.3	7
205	Management of Italian Patients With Advanced Non–Small-Cell Lung Cancer After Second-Line Treatment: Results of the Longitudinal Phase of the LIFE Observational Study. Clinical Lung Cancer, 2014, 15, 338-345.e1.	2.6	7
206	Hematopoietic growth factors in lung cancer. Current Opinion in Oncology, 2016, 28, 135-144.	2.4	7
207	Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: can we use enemy territory at our advantage?. Journal of Thoracic Disease, 2017, 9, 4300-4304.	1.4	7
208	Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2020, 21, 931-940.	1.8	7
209	Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial. Lancet Oncology, The, 2021, 22, 573-575.	10.7	7
210	Management of patients with cancer during the COVID-19 pandemic: The Italian perspective on the second wave. European Journal of Cancer, 2021, 148, 112-116.	2.8	7
211	A phase II study of pemetrexed and carboplatin as front-line chemotherapy in patients with malignant pleural mesothelioma (MPM). Journal of Clinical Oncology, 2005, 23, 7172-7172.	1.6	7
212	Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies Journal of Clinical Oncology, 2016, 34, e20522-e20522.	1.6	7
213	Host immuneâ€inflammatory markers to unravel the heterogeneous outcome and assessment of patients with <scp>PDâ€L1</scp> ≥50% metastatic nonâ€small cell lung cancer and poor performance status receiving firstâ€line immunotherapy. Thoracic Cancer, 2022, 13, 483-488.	1.9	7
214	A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe–Adria Thoracic Oncology Multidisciplinary group trial (ATOM) Tj ETQq0 0 0	rg B B/Ove	erlock 10 Tf 5
215	Management of Non-Small Cell Lung in Cancer Patients with Stable Disease. Drugs. 2012. 72. 20-27.	10.9	6 –

216Is the occurrence of a sigmoidal ventral border inCyprideis torosa(Jones) valves linked to salinity? A
morphometrical analysis approach. Journal of Micropalaeontology, 2017, 36, 70-79.3.66

#	Article	IF	CITATIONS
217	New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 19-33.	1.8	6
218	Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis. Annals of Translational Medicine, 2021, 9, 705-705.	1.7	6
219	Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?. American Journal of Clinical Dermatology, 2021, 22, 511-522.	6.7	6
220	COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report. Melanoma Research, 2021, 31, 490-493.	1.2	6
221	Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC. Cancer Research, 2018, 78, CT075-CT075.	0.9	6
222	Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial Journal of Clinical Oncology, 2012, 30, 7558-7558.	1.6	6
223	Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM) Journal of Clinical Oncology, 2015, 33, 7501-7501.	1.6	6
224	Mobile Emergency, an Emergency Support System for Hospitals in Mobile Devices: Pilot Study. JMIR Research Protocols, 2013, 2, e19.	1.0	6
225	Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis. Scientific Reports, 2022, 12, 1055.	3.3	6
226	Bevacizumab and non-small-cell lung cancer. Expert Opinion on Biological Therapy, 2007, 7, 1107-1119.	3.1	5
227	Dynamic behaviour of lactate values during mild hypothermia in patients with cardiac arrest. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 176-182.	1.0	5
228	Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers. Expert Review of Anticancer Therapy, 2016, 16, 1-4.	2.4	5
229	Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2017, 26, 551-561.	4.1	5
230	ll Costo Degli Eventi Avversi Associati ad Afatinib, Erlotinib e Gefitinib Nel Trattamento del Tumore del Polmone non a Piccole Cellule con Mutazione EGFR. Global & Regional Health Technology Assessment, 2017, 4, grhta.5000270.	0.1	5
231	Efficacy and safety data from patients with advanced non-squamous NSCLC and brain metastases from the nivolumab expanded access programme (EAP) in Italy. Annals of Oncology, 2017, 28, v469.	1.2	5
232	Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach. PLoS ONE, 2019, 14, e0224027.	2.5	5
233	Atezolizumab in a <u>C</u> o <u>H</u> ort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal Subtyp <u>E</u> s (CHANCE trial). Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091598.	3.2	5
234	Immune related adverse events and response to immunotherapy: Focus on corticosteroids. Lung Cancer, 2020, 145, 225.	2.0	5

#	Article	IF	CITATIONS
235	Serum levels of VCAMâ€1 are associated with survival in patients treated with nivolumab for NSCLC. European Journal of Clinical Investigation, 2022, 52, e13668.	3.4	5
236	PCSK9 as a new player in cancer: New opportunity or red herring?. Current Medicinal Chemistry, 2021, 28, .	2.4	5
237	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. Journal of Hematology and Oncology, 2022, 15, 9.	17.0	5
238	Phase II study of neoadjuvant chemotherapy in patients with surgically-proven, unresectable stage III non-small cell lung cancer. Anticancer Research, 2002, 22, 3519-24.	1.1	5
239	Penetration of Cefonicid into Serum, Salpinges, Cervix and Vaginal Tissue. Journal of Chemotherapy, 1991, 3, 28-29.	1.5	4
240	New perspectives for the pharmacological and biological therapy of small cell lung cancer. Critical Reviews in Oncology/Hematology, 1999, 31, 135-145.	4.4	4
241	Synthesis of new oxathiazinane dioxides and their in vitro cancer cell growth inhibitory activity. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5353-5356.	2.2	4
242	Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries. Current Medical Research and Opinion, 2016, 32, 1577-1584.	1.9	4
243	MA10.06 Impact of Immune-Related Adverse Events on Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab. Journal of Thoracic Oncology, 2018, 13, S390-S391.	1.1	4
244	Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. Lung Cancer, 2019, 134, 121-126.	2.0	4
245	Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC. Expert Review of Anticancer Therapy, 2021, 21, 705-713.	2.4	4
246	Managing patients with lung cancer. BMJ: British Medical Journal, 2000, 320, 379-379.	2.3	4
247	Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population Journal of Clinical Oncology, 2016, 34, 3067-3067.	1.6	4
248	To Treat or Not to Treat Advanced Non–Small-Cell Lung Cancer Patients With Impaired Performance Status?. Journal of Clinical Oncology, 2005, 23, 7231-7232.	1.6	3
249	PCN36 ECONOMIC EVALUATION OF ERLOTINIB, DOCETAXEL AND PEMETREXEDAS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). A COST-MINIMIZATION IN ITALIAN HOSPITALS. Value in Health, 2007, 10, A333.	0.3	3
250	A peer-education based disaster medicine course to turn medical students into a useful resource. International Journal of Disaster Risk Reduction, 2014, 8, 153-157.	3.9	3
251	Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. Lung Cancer, 2016, 100, 30-37.	2.0	3
252	Vinflunine for the treatment of non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2016, 25, 1447-1455.	4.1	3

#	Article	IF	CITATIONS
253	P2.01-067 The Relevance of CEA and CYFRA21-1 as Predictive Factors in Nivolumab Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Oncology, 2017, 12, S827-S828.	1.1	3
254	Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer. Cancers, 2019, 11, 441.	3.7	3
255	PD2.02 Pembrolizumab plus Pemetrexed-Platinum for Patients with Metastatic Nonsquamous NSCLC and Liver or Brain Metastases: Results from KEYNOTE-189. Journal of Thoracic Oncology, 2019, 14, S1170-S1171.	1.1	3
256	Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment. Clinical and Translational Oncology, 2020, 22, 1603-1610.	2.4	3
257	The Appropriateness of Invasive Ventilation in COVID-19 Positive Cancer Patients: Proposal of a New Prognostic Score. Viruses, 2021, 13, 508.	3.3	3
258	Phase II study of sunitinib in patients with non-small cell lung cancer (NSCLC) and irradiated brain metastases: Final efficacy and safety results Journal of Clinical Oncology, 2010, 28, 7581-7581.	1.6	3
259	Docetaxel (D) versus docetaxel/gemcitabine (D&G) in the treatment of older patients with advanced non-small cell lung cancer (NSCLC): An Alpe Adria Thoracic Oncology Multidisciplinary Group randomized phase II trial (ATOM 017) Journal of Clinical Oncology, 2010, 28, e18028-e18028.	1.6	3
260	Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib. Clinical Pharmacology: Advances and Applications, 2022, Volume 14, 1-9.	1.2	3
261	191 Pemetrexed in combination with carboplatin in elderly patients with malignant pleural mesothelioma. Lung Cancer, 2006, 54, S46.	2.0	2
262	B2-07: Impact of 3rd generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer (NSCLC): a meta-analytical approach. Journal of Thoracic Oncology, 2007, 2, S339.	1.1	2
263	9112 POSTER AVAPERL1 (MO22089) – Interim Safety of Maintenance (mtc) Bevacizumab (bev) + Pemetrexed (pern) in Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx). European Journal of Cancer, 2011, 47, S626.	2.8	2
264	A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 2012, 69, 369-375.	2.3	2
265	valutazione economica in base allo studio NAVOTRIALOT con riferimento al contesto sanitario italiano: Vinorelbine orale e Cisplatino o Pemetrexed e Cisplatino seguiti da mantenimento rispettivamente con Vinorelbine orale e Pemetrexed nel trattamento del Carcinoma Polmonare Non a Piccole Cellule Non Squamoso (NS-NSCLC) in stadio avanzato. Pharmacoeconomics Italian Research	0.2	2
266	Efficacy and safety of nivolumab in elderly patients (pts) with advanced squamous non small cell lung cancer (Sq-NSCLC) participating in the expanded access programme (EAP) in Italy. Annals of Oncology, 2016, 27, vi369.	1.2	2
267	P3.02c-095 Italian Nivolumab Expanded Access Programme: Efficacy and Safety Data inÂSquamous Non-Small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2017, 12, S1336-S1337.	1.1	2
268	MA 10.06 Real-World Results in Non-Squamous Non-Small Cell Lung Cancer Patients: Italian Nivolumab Expanded Access Program. Journal of Thoracic Oncology, 2017, 12, S1841.	1.1	2
269	Overall survival (OS) of selected patients (Pts) with non-small cell lung cancer (NSCLC) receiving nivolumab beyond progression. Annals of Oncology, 2017, 28, vi61.	1.2	2
270	Italian nivolumab expanded access programme: real-world results in non-squamous non-small cell lung cancer patients. Annals of Oncology, 2017, 28, v410-v411.	1.2	2

#	Article	IF	CITATIONS
271	KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?. Annals of Oncology, 2018, 29, viii529-viii530.	1.2	2
272	P2.14-02 Interim Survival Analysis of Gefitinib Plus Vinorelbine in Advanced EGFR-Mutant Non-Small Cell Lung Cancer (Genoa Trial). Journal of Thoracic Oncology, 2019, 14, S829-S830.	1.1	2
273	LBA82 Influenza-like illness and SARS-Cov-2 in the multicenter, prospective, observational INVIDIa-2 study (INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: A transversal) Tj ETQq1	1 0.17.184314	4 r g BT /Overla
274	Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer. Clinical Breast Cancer, 2020, 21, 218-230.e6.	2.4	2
275	1900P RAMES trial: A multicentre, double-blind, randomized, phase II study on gemcitabine plus ramucirumab versus gemcitabine alone as second-line treatment for advanced malignant pleural mesothelioma (MPM). Annals of Oncology, 2020, 31, S1078.	1.2	2
276	1277P An exosomal miRNA signature as predictor of benefit from immune checkpoint inhibitors in non-small cell lung cancer. Annals of Oncology, 2020, 31, S825-S826.	1.2	2
277	1765P Developing a risk assessment score for cancer patients during the COVID-19 pandemic. Annals of Oncology, 2020, 31, S1026.	1.2	2
278	Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110229.	3.2	2
279	A case of sudden brain metastases progression after temporary targeted therapy discontinuation: when to regret a drug holiday. Melanoma Research, 2021, 31, 190-193.	1.2	2
280	Title is missing!. Annals of Oncology, 1999, 10, 13-17.	1.2	2
281	Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 2007, 25, 18138-18138.	1.6	2
282	Should 3-weekly docetaxel (3WD) remain the standard for second-line therapy of advanced non-small-cell lung cancer (A-NSCLC)? Meta-analysis of 7 randomized clinical trials (RCTs) with 3WD comparator arms. Journal of Clinical Oncology, 2008, 26, 8087-8087.	1.6	2
283	Phase II trial of NGR-hTNF and doxorubicin in relapsed small cell lung cancer (SCLC) Journal of Clinical Oncology, 2011, 29, 7077-7077.	1.6	2
284	Evaluation of CTL antigen 4 (CTLA-4) expression as prognostic factor in non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2011, 29, e21157-e21157.	1.6	2
285	Potentiation of crizotinib activity by fasting cycles in an ALK+ lung cancer model Journal of Clinical Oncology, 2014, 32, e13511-e13511.	1.6	2
286	Surgical resection of superior pulmonary sulcus tumor after neoadjuvant chemoradiation via the anterior transmanubrial approach: a case report. Annals of Translational Medicine, 2021, 9, 1603-1603.	1.7	2
287	Administration of sunitinib to patients with non-small cell lung cancer and irradiated brain metastases: A phase II trial. Journal of Clinical Oncology, 2009, 27, 8077-8077.	1.6	2
288	Analysis of K-ras, p53, bcl-2 and Rb expression in non-small cell lung cancer cell lines. International Journal of Oncology, 1997, 11, 1203-8.	3.3	1

#	Article	IF	CITATIONS
289	Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. British Journal of Cancer, 2004, 91, 1428-1433.	6.4	1
290	Chemotherapy plus bevacizumab in the first-line treatment of non-small cell lung cancer: benefits, risks and limitations. Memo - Magazine of European Medical Oncology, 2008, 1, 13-16.	0.5	1
291	9014 POSTER DISCUSSION Randomized Phase II Trial of NGR-hTNF and Chemotherapy in Chemo-naive Patients With Non-small Cell Lung Cancer (NSCLC) -Preliminary Results. European Journal of Cancer, 2011, 47, S596.	2.8	1
292	Ribonucleotide reductase subunit 2 (RRM2) predicts shorter survival in resected stage l–III non-small cell lung cancer (NSCLC) patients. Lung Cancer, 2012, 77, S23.	2.0	1
293	3123 Correlation between circulating tumor biomarkers and positronemission tomography in advanced non-small cell lung cancer. European Journal of Cancer, 2015, 51, S644.	2.8	1
294	Afatinib for the treatment of non-small cell lung cancer. Expert Opinion on Orphan Drugs, 2015, 3, 1357-1364.	0.8	1
295	Italian nivolumab expanded access programme in non-squamous non-small cell lung cancer patients: Real-world results in never smokers and EGFR positive patients. Annals of Oncology, 2017, 28, v470-v471.	1.2	1
296	MA 11.11 Italian Nivolumab Expanded Access Program in Non-Squamous NSCLC Patients: Results in Never Smokers and EGFR Positive Patients. Journal of Thoracic Oncology, 2017, 12, S1847.	1.1	1
297	Reply to the Letter to the Editor by C. Nicolazzo et al.: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy― International Journal of Molecular Sciences, 2017, 18, 1309.	4.1	1
298	Successful treatment of lung adenocarcinoma with gefitinib based on EGFR gene amplification. Journal of Thoracic Disease, 2018, 10, E779-E783.	1.4	1
299	P1.01-53 Bone Metastases and Efficacy of Immunotherapy in Patients with Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2018, 13, S481.	1.1	1
300	Final results of randomized phase II trial of metronomic vs weekly oral vinorelbine (OV) as first-line chemotherapy (CT) in advanced NSCLC patients unfit to platinum-based CT (P-CT): Tempo-Lung. Annals of Oncology, 2019, 30, v646.	1.2	1
301	The elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer. Annals of Oncology, 2019, 30, v656.	1.2	1
302	Letter of response to comments on: Developing a risk assessment score for patients with cancer during COVID-19 pandemic: A war on two fronts. European Journal of Cancer, 2020, 140, 161-162.	2.8	1
303	COVID-19 Vaccination in Patients with Classic Kaposi's Sarcoma. Vaccines, 2021, 9, 632.	4.4	1
304	Fatigue: A main component of anemia symptomatology. Seminars in Oncology, 2001, 28, 15-18.	2.2	1
305	Vinflunine (VFL) in combination with gemcitabine (GEM) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): Preliminary results of the phase I and pharmacokinetic study. Journal of Clinical Oncology, 2005, 23, 7266-7266.	1.6	1
306	Irinotecan plus docetaxel in previously treated non-small cell lung cancer (NSCLC): An Alpe Adria Thoracic Oncology Multidisciplinary group phase II study (ATOM 007). Journal of Clinical Oncology, 2004, 22, 7363-7363.	1.6	1

#	Article	IF	CITATIONS
307	MicroRNA prognostic signature in malignant pleural mesothelioma Journal of Clinical Oncology, 2015, 33, 7562-7562.	1.6	1
308	PD-051 Final results of lung cancer and mesothelioma baselinescreening with low-dose spiral computed tomography (LDCT) in 1000 asbestos-exposed workers: An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 002). Lung Cancer, 2005, 49, S81.	2.0	0
309	P-584 Single agent gemcitabine (GEM) in performance status (PS) 2–3patients (pts) with advanced non-small cell lung cancer (NSCLC): Effect on disease-related symptoms in a multicenter phase II trial. Lung Cancer, 2005, 49, S272.	2.0	0
310	P-961 Buccal mucosa cells as "in vivo―model to evaluate gefitinib response in NSCLC patients. Lung Cancer, 2005, 49, S372-S373.	2.0	0
311	P-764 Phase II study of topotecan plus gemcitabine in previously treated small cell lung cancer (SCLC) patients: An Alpe-Adria Thoracic Oncology Multidisciplinary Group study (ATOM 012). Lung Cancer, 2005, 49, S320.	2.0	0
312	O2 Pemetrexed in combination with carboplatin in elderly patients with malignant pleural mesothelioma (MPM). Critical Reviews in Oncology/Hematology, 2006, 60, S18.	4.4	0
313	6612 POSTER Disease stabilization (SD) as a surrogate end-point in advanced non-small-cell lung cancer (NSCLC) patients treated with erlotinib (E) or gefitinib (G). European Journal of Cancer, Supplement, 2007, 5, 392.	2.2	Ο
314	125PD FINAL REPORT OF A RANDOMIZED PHASE II STUDY OF DOCETAXEL/OXALIPLATIN (DO) AND DOCETAXEL (D) IN PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS). AN ALPE-ADRIA THORACIC ONCOLOGY MULTIDISCIPLINARY GROUP STUDY (ATOM 019). Lung Cancer, 2009, 64, S53.	2.0	0
315	9007 ORAL Phase II Study of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker, in Patients With EGFR FISH-positive Advanced NSCLC. European Journal of Cancer, 2011, 47, S593-S594.	2.8	Ο
316	Corrigendum to "Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy―[Lung Cancer 69S1 (2010) S11–S18]. Lung Cancer, 2011, 71, 118.	2.0	0
317	9147 POSTER Treatment and Clinical Outcomes of Young Patients (^40 Years) With Advanced Non-small Cell Lung (NSCLC) – Data From a Retrospective Multicentric Database. European Journal of Cancer, 2011, 47, S637-S638.	2.8	0
318	1446 POSTER Evaluation of CTL Antigen 4 (CTLA-4) Expression as Prognostic Factor in Non-small Cell Lung Cancer (NSCLC). European Journal of Cancer, 2011, 47, S183.	2.8	0
319	The relevance of stable disease (SD) as a surrogate end-point in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib (E) as the second/third line. Lung Cancer, 2012, 77, S30-S31.	2.0	0
320	Ribonucleotide Reductase Subunit 2 (RRM2) Predicts Shorter Survival in Resected Stage I-III Non-Small Cell Lung Cancer (NSCLC) Patients. Annals of Oncology, 2012, 23, ix79.	1.2	0
321	Front-Line Chemotherapy with or without NGR-HTNF in Non-Small Cell Lung Cancer (NSCLC). Annals of Oncology, 2012, 23, ix410.	1.2	0
322	Afatinib in advanced non-small-cell lung cancer. Lung Cancer Management, 2013, 2, 493-504.	1.5	0
323	A Novel Prognostic Microrna Signature in Malignant Pleural Mesothelioma. Annals of Oncology, 2014, 25, iv542.	1.2	0
324	Efficacy of motesanib diphosphate in non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 1771-1780.	1.8	0

#	Article	IF	CITATIONS
325	Looking for results in non-small-cell lung cancer: is bio-chemotherapy the right answer?. Current Medical Research and Opinion, 2014, 30, 2291-2293.	1.9	Ο
326	Oral Vinorelbine Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-Line Treatment for Patients with Advanced non- Squamous non- Small Cell Lung Cancer: a Cost Minimization Analysis in Twelve European Countries. Value in Health, 2015, 18, A446.	0.3	0
327	3047 Oral vinorelbine (NVBo) and cisplatin (P) as first-line chemotherapy (CT) in Asian and Caucasian non small cell lung cancer (NSCLC) patients (pts): Meta-analysis of 3 randomised studies. European Journal of Cancer, 2015, 51, S612.	2.8	0
328	3099 Phase 3 trial (NGR015) of best investigator choice (BIC) with or without NGR-hTNF in previously treated malignant pleural mesothelioma (MPM). European Journal of Cancer, 2015, 51, S634.	2.8	0
329	Clinical applications of a next-generation sequencing panel in non-small cell lung cancer. Annals of Oncology, 2015, 26, vi87.	1.2	Ο
330	P3.02c-092 Nivolumab in Multi-Treated Patients with Advanced Sq-NSCLC: Data from theÂltalian Cohort of Expanded Access Programme (EAP). Journal of Thoracic Oncology, 2017, 12, S1334-S1335.	1.1	0
331	MA10.09 Comparison between CT Scan Evaluation Criteria and PERCIST for Evaluation of Immune Check-Point Inhibitors Response. Journal of Thoracic Oncology, 2017, 12, S401-S402.	1.1	Ο
332	MA 01.07 Lanreotide Maintenance in SCLC Expressing Somatostatine Receptors: Efficacy Results of Multicenter Randomized G04.2011 trial. Journal of Thoracic Oncology, 2017, 12, S1801.	1.1	0
333	P1.01-015 Crizotinib in ROS1 Rearranged or MET Deregulated Non-Small-Cell Lung Cancer (NSCLC): Final Results of the METROS Trial. Journal of Thoracic Oncology, 2017, 12, S1898.	1.1	Ο
334	The standard of care for stage III NSCLC in the era of immunotherapy: An Italian national survey on the current pattern of care among Italian thoracic oncologists. Annals of Oncology, 2018, 29, viii492.	1.2	0
335	Safety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial. Annals of Oncology, 2018, 29, viii506-viii507.	1.2	Ο
336	Randomised phase II trial of oral vinorelbine (OV) and cisplatin (P) followed by maintenance with OV versus gemcitabine (GEM) and P followed by maintenance with GEM as first-line chemotherapy in advanced non-small cell lung cancer (NSCLC) patients (pts) with squamous (sq) histological type. Annals of Oncology, 2018, 29, viii520-viii521.	1.2	0
337	P1.04-15 Computerized Tomography Texture Analysis as Biomarker of Benefit from Nivolumab in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, S531.	1.1	Ο
338	P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated with Nivolumab. Journal of Thoracic Oncology, 2018, 13, S730-S731.	1.1	0
339	P1.01-73 Preliminary Results of the SENECA (SEcond Line NintEdanib in Non-Small Cell Lung CAncer) Trial: An Italian Experience. Journal of Thoracic Oncology, 2018, 13, S490-S491.	1.1	Ο
340	P2.03-28 Whole Exome Sequencing to Discover Lung Tumor Predisposition in Women with Previous Breast Cancer. Journal of Thoracic Oncology, 2018, 13, S726-S727.	1.1	0
341	Lung cancer predisposition in women with previous breast cancer identified by whole exome sequencing. Annals of Oncology, 2018, 29, viii674.	1.2	0
342	Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial. Annals of Oncology, 2019, 30, v645-v646.	1.2	0

#	Article	IF	CITATIONS
343	PC05.02 Are ICIs Effective for Poor Performance Status Patients with Advanced NSCLC?. Journal of Thoracic Oncology, 2019, 14, S145-S146.	1.1	0
344	P1.04-45 Immune-Oncology Gene Expression Profiles Allow Lung Cancer Patients' Stratification and Identification of Responders to Immunotherapy. Journal of Thoracic Oncology, 2019, 14, S458.	1.1	0
345	P2.04-84 NSCLC Survival Expectancy for Patients Treated with Docetaxel/Nintedanib in the SENECA Trial and Previous Immunotherapy. Journal of Thoracic Oncology, 2019, 14, S742-S743.	1.1	0
346	1318P Association between soluble PD-L1 and prognosis of non-small cell lung cancer (NSCLC) patients treated with immunotherapy. Annals of Oncology, 2020, 31, S851.	1.2	0
347	1689P The appropriateness of invasive ventilation in COVID-19 positive cancer patients: The hardest decision for oncologists. Annals of Oncology, 2020, 31, S998-S999.	1.2	0
348	1696P Incidence of influenza-like illness (ILI) in cancer patients during COVID-19: The ONCOVID prospective observational study. Annals of Oncology, 2020, 31, S1001.	1.2	0
349	1705P SARS-CoV-2 infection among cancer patients receiving antitumor treatment in Italy: A nationwide observational study (CIPOMO ONCO COVID-19). Annals of Oncology, 2020, 31, S1004-S1005.	1.2	0
350	Cancer Mechanisms and Emerging Therapies. Pharmaceutics, 2021, 13, 1045.	4.5	0
351	Lung cancer and mesothelioma screening with low-dose spiral computed tomography (LDCT) in 1,000 asbestos-exposed workers: An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM) Tj ETQq1 1	0.78 £8 14 ı	rgBƊ/Overloc
352	Impact of gemcitabine (G) on the activity of first-line chemotherapy in non-small cell lung cancer (NSCLC): A meta-analysis. Journal of Clinical Oncology, 2006, 24, 7138-7138.	1.6	0
353	Second line chemotherapy with topotecan and gemcitabine in small cell lung cancer (SCLC) patients: An Alpe-Adria Thoracic Oncology Multidisciplinary group phase II study (ATOM 012). Journal of Clinical Oncology, 2006, 24, 17014-17014.	1.6	0
354	Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant subsets of stage IIIA N2 non-small cell lung cancer patients. An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 014). Journal of Clinical Oncology, 2006, 24, 10085-10085	1.6	0
355	Randomized phase II trial of two sequential schedules of docetaxel (D) and cisplatin (C) followed by gemcitabine (G) in patients with advanced non-small cell lung cancer. Journal of Clinical Oncology, 2007, 25, 18154-18154.	1.6	0
356	Final report of a randomized phase II study of docetaxel/oxaliplatin (DO) and docetaxel (D) in previously treated non-small cell lung cancer (NSCLC) patients (pts). A novel design, Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 019). Journal of Clinical Oncology, 2009, 27, e19010-e19010	1.6	0
357	Optimal duration of chemotherapy (CT) for advanced non-small cell lung cancer (NSCLC) in the first- and second-line settings. Journal of Clinical Oncology, 2009, 27, e19037-e19037.	1.6	0
358	Treatment and clinical outcome of young (age 40 and younger) patients with advanced non-small cell lung (NSCLC) Journal of Clinical Oncology, 2010, 28, e18117-e18117.	1.6	0
359	ERCC1, BRCA1, thymidylate synthase (TS), class III beta tubulin (bTubIII), p53R2, RRM2 immunohistochemical expression in stage I-III non-small cell lung cancer (NSCLC): A tissue microarray (TMA) study Journal of Clinical Oncology, 2010, 28, e21094-e21094.	1.6	0
360	Phase II study of NGR-hTNF, a vascular targeting agent, in combination with doxorubicin in patients with relapsed small cell lung cancer (SCLC) Journal of Clinical Oncology, 2010, 28, e18043-e18043.	1.6	0

#	Article	IF	CITATIONS
361	Randomized, phase II trial of NGR-hTNF and chemotherapy in chemotherapy-naive patients with non-small cell lung cancer (NSCLC): Preliminary results Journal of Clinical Oncology, 2011, 29, 7568-7568.	1.6	0
362	Abstract 5649: Investigational study of acquired resistance to the EGFR irreversible inhibitor afatinib (BIBW2992) in wild-type and EGFR-mutant NSCLC cell lines , 2013, , .		0
363	Serum mass-spectrometry test in first-line advanced NSCLC patients treated with standard chemotherapy regimens Journal of Clinical Oncology, 2014, 32, e19090-e19090.	1.6	0
364	The role of circulating free DNA (cfDNA) and circulating tumor cells (CTC) in advanced non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy (CHT) Journal of Clinical Oncology, 2015, 33, e19090-e19090.	1.6	0
365	Abstract 4008: MiRNA expression profiling reveals a prognostic signature in malignant pleural mesothelioma. , 2015, , .		0
366	Abstract 2521: In vitro and in vivo antitumor efficacy of sequentially combined vinorelbine and gefitinib in non-small cell lung cancer. , 2015, , .		0
367	Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer (SCLC): GOIRC-AIFA FARM6PMFJM trial Journal of Clinical Oncology, 2016, 34, 8513-8513.	1.6	0
368	Screening with low-dose computed tomography (LDCT) of asbestos-exposed subjects and lung cancer (LC) mortality Journal of Clinical Oncology, 2016, 34, 1554-1554.	1.6	0
369	Randomized phase II trial of oral vinorelbine (OV) and cisplatin (P) followed by maintenance with single-agent OV <i>versus (vs)</i> gemcitabine (GEM) and P followed by maintenance with single-agent GEM as first-line chemotherapy (CT) in locally advanced (LA) or metastatic non-small-cell lung cancer (NSCLC) patients (pts) with squamous (sq) histological type Journal of Clinical Oncology, 2018, 36,	1.6	0
370	ez1058-ez1058. Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial. Annals of Oncology, 2019, 30, ix172.	1.2	0